AbbVie stirs safety jitters after two patients die in ABT-494 study
AbbVie $ABBV revealed that two rheumatoid arthritis patients died in its late-stage work on ABT-494, which quickly triggered a case of the jitters for a drug touted as a major part of the company’s late-stage pipeline hopes.
According to researchers, the two patient deaths include one for unknown causes. A second patient in the 30 mg dose group came down with a fever and had problems with diarrhea. The subject subsequently experienced heart failure and presumed pulmonary embolism.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.